Bluebird bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023 at 07:04 am EDT
Share
bluebird bio, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 6.89 million compared to USD 1.52 million a year ago. Net loss was USD 72.91 million compared to USD 100.14 million a year ago. Basic loss per share from continuing operations was USD 0.67 compared to USD 1.36 a year ago. Diluted loss per share from continuing operations was USD 0.67 compared to USD 1.36 a year ago.
For the six months, revenue was USD 9.27 million compared to USD 3.46 million a year ago. Net loss was USD 51.67 million compared to USD 222.29 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 3.02 a year ago. Diluted loss per share from continuing operations was USD 0.49 compared to USD 3.02 a year ago.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).